Home » News » Significant Refundable R&D Offsets receipts reported to the ASX in recent months

Significant Refundable R&D Offsets receipts reported to the ASX in recent months

July 8th, 2024

Over recent months, a number of companies have reported to the ASX receipt of substantial Refundable R&D Tax Offsets.

Notable receipts include:

  • Recce Pharmaceuticals (ASX: RCE) received $2.6 M related to its anti-infective platform;
  • Latrobe Magnesium (ASX: LMG) received $12.5 M related to Magnesium extraction technology;
  • Group 6 Metals (ASX:G6M) received $14.3 M related to processes for producing higher value tungsten products
  • Orthocell Limited (ASX: SNT) received $3.05 M related to its mobility regeneration technology;
  • Botanix (ASX: BOT) received $3 M related to its dermatology technology

The diversity of companies and projects receiving reviews evidences a key benefit of the R&D Tax Incentive being a broad based, market driven system.

Receipt of a tax offsets reduce the need for a company to raise additional capital to complete trials or further R&D, and could make pathway to commercialisation exponentially easier.

Please get in touch with our office if you require assistance, would like to speak to someone about a potential claim, or check out our website for more information.

Post a Comment

(*) indicates required field.

Are You Eligible?


Click here for the R&D Eligibility Wizard

R&D Audit Checklist


Click here for the R&D Eligibility Wizard

Categories

Archives